FAQs

General

Can I participate in research?

Yes. There are observational (clinical database) studies and therapeutic research trials ongoing. Click here to learn more about participating in MCC research.

Do normal Merkel cells turn into Merkel cell carcinoma?

The answer to this question is not known with certainty, but multiple lines of evidence suggest that Merkel cell carcinoma does NOT derive directly from normal Merkel cells. This is in part because it has proven impossible to get a normal Merkel cell to divide and grow. It is more likely that the precursor of a normal Merkel cell (a stem cell in the epidermis) gives rise to both the normal Merkel cell and separately, to Merkel cell carcinoma. There are several studies that have determined that normal Merkel cells are derived from epidermal precursor cells.

Does a patient support group exist for MCC?

An active support group exists for MCC. Learn more about getting support and joining support groups with other MCC patients and their friends and family members.

Is MCC hereditary/are my children more likely to get MCC?

There are no data suggesting that MCC runs in families. However, in general people, with light skin are at risk for all types of skin cancers. In fact, there are no reported cases of MCC occurring in multiple members of one family. However, through our cohort of over 1000 patients and others who have contacted us directly, we are now aware of four separate families in which two closely related family members had MCC. We do not think this supports the notion that MCC risk particularly runs in families.

What causes MCC?

Recent genetic studies have shown that Merkel cell carcinomas are caused either by mutations induced by sunlight or by the Merkel cell polyomavirus. Risk factors strongly associated with the development of MCC include fair skin, a history of extensive sun exposure, chronic immune suppression (kidney or heart transplantation or HIV), and over age 50.

What does MCC look like?

MCC usually develops on sun-exposed skin as a firm, painless, flesh-colored to red-violet bump. The initial small bump tends to grow rapidly over weeks to months. Some images can be seen on our Clinical Photos page.

What is a lymph node?

The lymphatic system is a system of vessels and lymph nodes throughout the body. It serves an important function in the immune system. Lymph nodes act as filters to trap cancer cells as they travel through the lymphatic vessels. The lymph nodes that filter the legs are in the inguinal region between the thigh and the abdomen. The lymph nodes that filter the arms are in the armpit (axilla). Those that drain the skin of the face can be under the chin (submandibular), along the neck (cervical), or around the ears (pre/post-auricular).

What is a Merkel cell?

Merkel cells are found in the epidermis (outer layer of the skin). Although the exact function of Merkel cells is unknown, they are thought to be touch receptors. They have both sensory and hormonal functions and are sometimes referred to as neuroendocrine cells. Learn more about Merkel cells.

What is an antibody titer?

The antibody titer is the standard measure of how much of a particular antibody is in the blood. The titer value increases as the amount of that antibody increases in the blood.

What is an antibody?

An antibody is a highly specific protein made by our bodies that can recognize and bind to an agent such as a bacteria or virus.

What is Merkel cell carcinoma (MCC)?

MCC, also referred to as neuroendocrine carcinoma of the skin, arises from uncontrolled growth of cells that share some characteristics with normal Merkel cells of the skin. It is a rare skin cancer with an incidence of about 2,000 cases per year in the US, and this number is continuing to increase. MCC will prove fatal in roughly 1/3 of patients and should receive prompt, but appropriately customized treatment.

What issues should I be sure to discuss with my physicians?

Merkel cell carcinoma is rare, so it is common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team be knowledgeable, as they will need to execute the plan that MCC specialists will create. Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed about MCC and how to care for patients.

Where does MCC occur on the body?

MCC primarily occurs on highly sun-exposed skin such as the head/neck and arms, but it can occur anywhere on the body, including sun-protected areas such as the buttock. Learn more about the symptoms and appearance of Merkel cell carcinoma.

Who gets MCC?

Individuals over the age of 65 are far more likely to develop MCC. Fair skin and a history of extensive sun exposure also increase the chances. MCC is associated with weakened immune function, such as in patients with HIV or organ transplants. However, over 90% of people who get MCC have no known immune suppression.

Disease Stages

Are there aspects of holistic or complementary care that make sense for all cancer patients?

Yes. Ensuring that cancer patients have a good diet, sufficient exercise, and a realistic but optimistic outlook is likely to improve the efficacy of traditional cancer care as well as quality of life.

What are the main differences between the 7th & 8th Editions of the AJCC Staging Systems for MCC?

It has recently been realized that MCC patients with nodal disease who have no known primary lesion do better than node-positive patients who still have a primary lesion in place.  These two categories of Stage III (nodal) disease are separated in the new system, resulting in more accurate prediction of recurrence. In the 8th Edition system, it is now necessary to note whether staging was ‘clinical’ or ‘pathologic’ (see table in 8th Edition system) for a summary.

ICD Codes

At what point during treatment of a patient diagnosed with MCC would we code the patient visit as prior history of MCC?

There is no cut off time. In the past, people have used 5 years as the cut off but that is no longer applicable since treatments are much more effective now. The guidelines for coding malignancy state: “When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy, a code from category 285.821: Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy.” The intent of the history codes (in the cases of history of MCC you would use 285.821) is to indicate that the condition no longer exists and is not receiving any treatment, but that has the potential for recurrence, and therefore may require continued monitoring.”

How does one code MCC recurrence? Would one have to list both prior history along with code for the current lesion ?

If the recurrence happened after treatment had ended and the patient was in the history phase, then it would be coded using a Chapter 2-Neoplasms code for the new malignancy (even if it is recurring at the site of the previous malignancy) AND ALSO code 285.821 to show that there was a history.

What does MCC of other site include for ICD codes? Are there any other site other that can be included in this code?

Currently the index includes the sites of genital and buttock to code C4A.8: Merkel cell carcinoma of other sites. We also include “specified site not elsewhere classified” to this code (C4A.8) in case a site would be documented that is not specifically in the index.

Prognosis

How are metastases detected?

A physical exam may reveal a new skin lesion, an enlarged lymph node or an enlarged liver that may signal the spread of MCC. A lesion of metastatic MCC may appear as a 1-3 cm, flesh-colored to red-purple bump that feels firm, is deeper compared to the primary lesion, and grows rapidly over a period of 2-4 weeks. The AMERK serology test can be an inexpensive, safe and sensitive approach to detect early recurrence. See the Symptoms and Appearance of MCC page for common sites of MCC metastasis. Blood tests, such as liver function tests (LFTs), may be used to detect the spread of MCC to internal organs, such as the liver. If a doctor is suspicious of distant metastases, he or she may use non-invasive imaging techniques, such as chest X-ray, CT (computed tomography) scans, and PET (positron emission tomography) scans.

How can I increase my chances of survival?

You can increase your chance of survival by working with a team of doctors that is familiar with the unique management of MCC. In most cases, getting a baseline scan and a sentinel lymph node biopsy is the best way to determine how advanced your cancer is. MCC is not the same as small cell lung cancer, and thus should not typically be treated with chemotherapy alone. Similarly, MCC is not the same as melanoma, and thus extra consideration should be taken before treating with surgery alone. Another important aspect of your treatment is to continue to eat a healthy diet and get regular exercise to help keep your immune system and overall health strong.

Should all patients participate in complementary or alternative therapies for their cancer?

No. Participation in these ‘scientifically unproven’ approaches to cancer therapy should be strictly voluntary.  Some patients are very keen to use these approaches and others have no interest. We never push our patients to engage in any specific alternative approach.

What are my chances of beating Merkel cell carcinoma?

Your chance of beating MCC depends on how advanced the disease was when it was diagnosed, what treatment you receive and if your immune system is functioning properly. The “stage” of your cancer refers to whether the cancer is only in the skin, has spread to the lymph nodes or has spread elsewhere in the body. In general, about 1/3 of all MCC patients will succumb to this disease.

What immune problems make beating MCC more difficult?

People with severe defects in “T lymphocytes” (key cells of the immune system) have a 10-30 times greater chance of developing MCC and twice the chance of losing the battle with MCC compared to people with a normal immune system. The conditions that cause such severe T lymphocyte defects include HIV (AIDS), taking immune suppressive drugs after solid organ transplantation, and certain immune cancers such as chronic lymphocytic leukemia. In contrast, suffering from more “colds” than average will not importantly affect your ability to fight MCC.

What kind of follow-up do I need?

After your initial treatment, you will need to be followed closely by a physician to do regular skin and lymph node exams and take a thorough history. Visits should be approximately every 3 months for year 1 and then every 3-6 months for year 2, and then annually after that.

Serology

After a patient has received treatment for his/her MCC, when will his/her oncoprotein antibody titer become negative?

Even after treatment, some people’s oncoprotein antibody titers may never become fully negative. Patients may stabilize at a low positive oncoprotein antibody titer (<2000). Regardless, a significant decrease in oncoprotein antibody titers is expected after treatment.

Among patients who made oncoprotein antibodies at diagnosis, what does a falling (or newly negative) titer mean?

Among 230 tests with falling or newly negative titers, the patient had no evidence of disease recurrence in 226 instances. In this setting, surveillance per routine guidelines (available via nccn.org) should be followed.

Can serology be used to diagnose or screen for MCC?

The serology test is NOT meant for diagnostic or screening purposes, since MCC can only be diagnosed through a biopsy.

Does a patient need to be fasting for the blood draw?

No, a patient can give blood at any time of day and does not need to fast.

Does serology indicate whether or not a patient has the virus in their cancer?

If a patient is positive for the oncoprotein antibody, then he has the Merkel virus in his cancer. If a patient is negative for the oncoprotein antibody, it is not clear whether or not he has the virus in his cancer.

How can doctors order the serology test?

A patient’s medical team must fill out the order form and ship the sample to UW Lab Medicine in Seattle.

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

How fast should oncoprotein antibody titers be falling?

The rate of decrease in antibody titers varies from patient to patient, but typically will fall by more than half in the first year.

How often and for how many years should a patient have this test run?

For patients who make oncoprotein antibodies, we typically recommend an interval of 3 months between two tests. Depending on the stage of the disease and other risk factors, after 3 to 5 years patients and their medical teams may choose to run the test less often or discontinue it.

How was the serology test developed?

The dedicated research efforts of the Moore-Chang Lab, Galloway Lab, Nghiem Lab and UW Clinical Immunology Lab were integral to this research.

If a patient does not make oncoprotein antibodies, does that lower his chances of beating MCC?

Ongoing analysis of our results suggests that survival may be improved among patients who make oncoprotein antibodies. Whether or not patients make these antibodies does not currently affect how we treat MCC.

If it turns out that the serology test is not useful for a patient (because they don’t make antibodies), how will the disease be monitored?

If a patient does not make oncoprotein antibodies when he has the disease, then the serology test won’t be helpful for monitoring. However, the patient should continue regular clinical visits and imaging studies as recommended by his medical team.

If the oncoprotein antibody titer is rising, how likely is it that there is a recurrence?

Among 23 tests with increasing titers, there was evidence of disease recurrence in 14 instances.

Is it better to have a higher titer of Merkel virus oncoprotein antibodies?

A higher titer of oncoprotein antibody is not directly associated with any change in the chances of beating the cancer. One cannot compare the values across patients because the antibody titers are only meaningful if tracked over time for an individual patient. Changes in antibody titers are more important than the specific titer value itself.

Is this test useful for ongoing tracking of disease burden in patients who have MCC that can be seen on physical or radiological exams?

After determining whether a patient makes these antibodies, we do not use this test if MCC remains clinically detectable. In such cases, it is preferable to track known disease using radiologic imaging or physical exam as appropriate.

What are the risks or side effects of the testing procedure?

The testing procedure involves a small-volume blood draw. No major risks or side effects of the testing procedure have been identified.

What does a borderline oncoprotein antibody result mean?

Patients with a borderline result (a titer of 75-150) for the oncoprotein antibody test at a time when MCC was present may or may not make antibodies to the oncoprotein. The effectiveness of monitoring through the serology test is unclear in such patients.

What does it mean if a patient had an increase in oncoprotein antibody titer and his scan does not show any obvious disease?

There are 2 possible explanations: The test result is inaccurate There may be a very small MCC recurrence that can not be seen on the scan and that the patient’s immune system may or may not eliminate A follow-up serology test and imaging study may be indicated in a few months.

What does it mean to be positive or negative for “capsid” antibodies?

A positive capsid antibody result means a person has been exposed to the Merkel virus in the past. It does not have any bearing on whether the person has active MCC. Capsid antibodies cannot be used to track the disease.

What does it mean to be positive or negative for “oncoprotein” antibodies?

Only 50% of newly diagnosed MCC patients make oncoprotein antibodies. A negative test for oncoprotein antibodies when a patient has the disease means that the patient does not make antibodies and therefore the serology test will not be a useful tool to monitor the disease. A positive test for oncoprotein antibodies (titer>150) means that the serology test can be used to track the disease, and we would expect antibody titers to decrease after the cancer is successfully treated.

What does the Merkel serology test detect?

This test detects antibodies to the oncoprotein of the Merkel virus in the blood.

What is concerning for recurrence?

If a patient is receiving regular serology tests, an increase in oncoprotein antibody titers – with or without symptoms – is concerning for a recurrence. An increase in oncoprotein antibody titers should be discussed with the patient’s physician who may consider ordering an imaging study.

What is the cost of the serology test?

As of 2019, the charge for UW Lab Medicine to perform this test will be approximately $600 the first time the test is performed. Subsequent tests will cost approximately $300. The facility that orders the test will also charge for the blood draw, isolating serum, shipping and tracking the sample, recording and reporting the results. The total cost will therefore vary significantly between facilities.

What is the Merkel virus?

The Merkel virus was first discovered in 2008 (by Patrick Moore and Yuan Chang’s group) and is now known to play a role in >80% of Merkel cell carcinomas (MCCs). The virus is commonly found on people’s normal-appearing skin and typically causes no problems. Important components of this virus include: The capsid protein (VP1) is a structural protein on the outer layer of the virus. The oncoprotein (T-antigen) is a separate protein encoded by the virus.

What is the sensitivity of the oncoprotein antibody test?

The ‘sensitivity’ of a test reflects the ability of the test to find the disease when it is present. The sensitivity of the oncoprotein antibody test is 78%.  The data used to calculate these numbers are below in the ‘2 by 2’ table among 253 samples. First Recurrence Evidence of Disease Recurrence Serology Test Results Positive Negative Increasing 14 4 Decreasing 4 226

What is the specificity of the oncoprotein antibody test?

In general, the ‘specificity’ of a test reflects how accurately the test identifies absence of disease among those who are without disease. The specificity of the oncoprotein antibody test is 98%.

What type of facility should I go to in order to have my blood drawn for this test?

In general, labs at larger hospitals are more accustomed to drawing and processing blood.

Where can I find technical details regarding sample collection and handling relating to this test?

See the UW Laboratory Test Catalog here.

Who could benefit from the serology test?

This test is for patients with biopsy-proven MCC who want to monitor their disease status for recurrence.

Who funded the research for this serology test?

The research was funded in part through grants from the National Institutes of Health (NIH), the American Cancer Society (ACS) and many generous donors.

Who should NOT receive the serology test?

This test is not useful for MCC patients who did not have oncoprotein antibodies at a time when they had evidence of MCC.

Who will receive the results?

The results will be sent to the ordering physician’s office typically in less than one month.

Will insurance cover the cost of the test?

As this test is for a rare disease, different insurance companies may or may not cover the cost of the test.

Testing & Diagnosis

Do I need scans?

CT scans (or “CAT” scans), X-rays, MRI, bone scan and PET scans are different types of imaging to look inside the body. They are sometimes used to find cancer inside the body that is not evident from the outside. There is a lot of controversy about how to use such scans. They are particularly important if MCC has been found to have spread to the lymph nodes to evaluate if significant disease has also developed elsewhere. In general, scans are far less effective in detecting early spread than a sentinel lymph node biopsy. Learn more about testing for MCC.

How does MCC metastasize?

Cancer cells from an MCC tumor can break off and go into the lymphatic system or the blood. These cells can then go elsewhere in the body where they can either be killed by the immune system or take residence in a new location and start growing as a metastasis (tumor in another part of the body).

How does staging work for MCC?

In general, cancers are staged according to where the cancer is in the body: local (skin only), nodal (involves the lymph nodes), or metastatic (spread elsewhere in the body). The best survival is for local stages; the poorest is in metastatic stages with nodal disease somewhere in between. In the past, there were five different staging systems for MCC, and this created confusion. The AJCC 7th Edition Staging Manual, which is the first international “consensus” staging system, will be officially replaced by the 8th Edition at the start of 2017.

Is it very challenging for a pathologist to make the diagnosis of MCC?

While an MCC on the skin can look quite unconcerning (like a cyst or folliculitis lesion), under the microscope, MCC can easily be identified as a cancer of the ‘small blue round cell’ category.  When a lesion falls into that category, the pathologist almost always orders a set of tests as described above (CK20, TTF1, etc). In the vast majority of cases, the pattern of CK20 and other tests makes the diagnosis of MCC quite easy for the pathologist.

What are the advantages of a sentinel lymph node biopsy?

Because MCC has already spread to the adjacent lymph nodes that feel normal in nearly one third of cases at diagnosis, figuring out whether this has happened or not helps in properly “staging” a patient, and thus in more accurately predicting the chance the cancer will recur. If the nodes are involved, treating them with radiation or surgery markedly reduces the risk the cancer will come back in those nodes.

What is the best way to decide if an MCC patient should have radiation?

While there is agreement that radiation therapy lowers the risk of MCC recurrence, there is great controversy as to exactly which patients should receive this therapy.  The side effects, cost, and inconvenience of radiation therapy can be significant. Patients with extremely low risk disease should not receive radiation, and patients with high risk disease should be offered this therapy. Determining which moderate-risk disease patients should receive radiation is very tricky and needs to be customized for each patient’s philosophy regarding recurrence risk versus side effects.  Ideally, this discussion should take place with a multi-disciplinary team that is very familiar with the relevant literature and the risks and benefits of radiation therapy for MCC.

When should the sentinel lymph node biopsy performed?

It is important to perform a sentinel lymph node biopsy at the time of (or prior to) a significant re-excision surgery.  This is because extensive surgery at the site of the tumor disrupts the tiny lymphatic vessels that connect the tumor to the regional 1-2 lymph nodes where the cancer may have spread microscopically.

Where can MCC spread?

MCC can spread to other areas of the skin, the lymph nodes, or anywhere else in the body including the liver, bone, lung, and brain.

Treatment

Can Mohs surgery be done at the same time as a sentinel lymph node biopsy?

Typically not. Mohs surgery is typically done in a dermatologist’s office. A sentinel lymph node biopsy is typically done in an operating room by a surgical oncologist, using general anesthesia.  If a patient needs a node biopsy, it typically needs to be done in advance of Mohs surgery, by a different physician.

Do I need a sentinel lymph node biopsy?

A sentinel lymph node biopsy (SLNB) is a procedure in which a radioactive dye is injected near the primary tumor site, and the one to three nearby lymph nodes that “light up” (take up the dye) are removed by the surgeon and sent for pathologic examination (microscopic evaluation by a pathologist). This SLNB procedure is usually performed at the time of surgery and is much less accurate if a wide surgical excision has already been done. SLNB is important because MCC can spread by lymphatic vessels very early in the disease. At such a time, disease spread is not detectable by palpation (feeling the lymph nodes) or by scans but is readily detected by this test. For these reasons, SLNB is the best way to determine if MCC has spread elsewhere in the body, and it can help determine if the local lymph nodes require treatment.

Do I need chemotherapy?

In general, chemotherapy is reserved for late stages of MCC, when immune therapies are not an option. For disease that is not metastatic, good control can often be achieved with surgery and radiation alone.

Do I need surgery?

A surgical excision is usually performed after a diagnostic biopsy as the first step of appropriate treatment for MCC. The goal of surgery is to remove any remaining cancer that can be seen either by the naked eye or under a microscope.

How could a patient get access to an Immune checkpoint inhibitor for MCC?

Immune checkpoint inhibitors are given through clinical trials, off-label, or compassionate use (where the pharmaceutical companies pay for the therapy).

How should MCC be treated?

In most cases, complete surgical excision of the tumor should be carried out immediately following a sentinel lymph node biopsy procedure. After a few weeks of healing, in many cases, radiation therapy to the primary tumor site and sometimes the draining lymph node area may be appropriate. If no cancer remains after surgery and radiation, we do not typically recommend adding adjuvant chemotherapy for a variety of reasons as outlined here. Learn more about MCC treatment options.

How should my treatment plan be determined?

Your MCC case should be reviewed by a multidisciplinary team including surgical oncologists, radiation oncologists, medical oncologists, and dermatologists with significant experience in managing MCC to develop a plan that could then be carried out by your local physicians. It is important that you and your doctors realize that optimal management of MCC is different than that for small cell lung carcinoma and for melanoma. The most significant difference is the important role of radiation in managing many cases of MCC. Another important difference is that adjuvant chemotherapy has not been shown to improve survival in MCC. Learn more about treatment options for MCC.

What are the requirements for Merkel cell carcinoma clinical trials?

Every clinical trial has a different set of requirements, and can limit enrollment based on age, tumor size, extent of disease, past treatments and immune status.

What immune checkpoint inhibitors are FDA-approved for MCC?

Avelumab (Bavencio) is the first and only FDA-approved immunotherapy drug for MCC. Avelumab has received orphan drug and breakthrough drug status for its use in MCC. Pembrolizumab was recently listed as a treatment option for patients with metastatic MCC on the NCCN guidelines. This drug is approved by the US FDA for treatment of other cancers and can be prescribed by oncologists outside of clinical trials. 

What is single-fraction radiation for MCC?

In some cases, especially if MCC has spread beyond the local-nodal area, we have successfully used a single, larger dose (8 Gy) of radiation to shrink and sometimes eliminate a given metastatic lesion. This approach has relatively few side effects and may work nicely together with systemic immune stimulation therapy.  We described this approach in a 2015 report on 93 tumors treated in 26 patients.

What is the correct surgical margin size for a Merkel cell carcinoma?

This is an extremely tricky and controversial point. If radiation will be used, then surgical margins can be very small and narrow (just taking out the obvious portion of the tumor provides superb results when combined with adjuvant radiation). In contrast, if radiation is not planned, margins that are greater than 1 cm (ideally 2 cm) are associated with a lower risk of recurrence.

What kind of treatments are administered on Merkel cell carcinoma clinical trials?

Typically, MCC clinical trials administer immune checkpoint inhibitors but also include chemotherapy, certain types of radiation, and combinations of therapies. Please explore the National Institutes of Health’s website to learn more about active MCC clinical trials, their eligibility, and location sites.

When is surgery alone sufficient for treating Merkel cell carcinoma (no radiation)?

This is an extremely controversial area. Some studies, including ones led by the Bichakjian and Coit teams, suggest that MCCs can be treated with surgery alone, with very few patients experiencing relapse. Other studies suggest that radiation cuts the risk of local recurrence by 2-3 fold. A reasonable approach is that surgical excision alone is likely sufficient for certain low-risk tumors. For example, no radiation is usually needed if the tumor is relatively small (<2cm), the sentinel lymph node biopsy is negative, larger surgical excision margins are achieved (typically about 2cm), there is no lymphovascular invasion noted by the pathologist, if the pathologist cannot find any tumor cells at the margin, and if the patient is not immune suppressed. If these higher risk factors are present, it means there would likely be greater benefit of adding radiation therapy.

#8211

#8212

#8220

≤ 2 cm maximum tumor

1:30-2:30 pm et

1.7 cm in diameter

13th

13th congress

15%

2 cm maximum tumor

2 cm maximum tumor dimension

2 cm tumor dimension

2 nd primary

2 patients

2007

2009

2014

2015

2016

2017

2018

2018 dinner

2019

2019 1:30-2:30 pm

2019 1:30-2:30 pm et

2019 dinner

21 2016

400

60% of patients

6th annual

6th annual harley

6th annual harley haynes

6th annual harley haynes lectureship

8 th edition

8th edition

8th edition ajcc staging

8th edition ajcc staging system

8th edition staging

8th edition staging system

8th edition system

95%

95% ci

ability

abstract

academy

academy of dermatology

activate the patient's immune

activate the patient's immune system

activity

adam trial

adapted from agelli 2003

adapted from perrott 2003

adjuvant chemotherapy

adjuvant radiation therapy

advanced

advanced mcc

advice

agent gla-se for merkel

agent gla-se for merkel cell

aggressive

aggressive behavior

aggressive immunogenic

aggressive immunogenic cancer

ahronowitz u california san francisco

ajcc 8th

ajcc 8th edition

ajcc 8th edition system

ajcc staging manual 8th

ajcc staging manual 8th edition

ajcc staging system

akaike

al nejm 2016

alfred

alfred marchionini

allison

allison blankemeyer

alternative approaches

alternative therapies

american

american academy

american academy of dermatology

amerk serology test

amp

analyses

analytics

andrew schorr

annual

annual harley

annual harley haynes

annual harley haynes lectureship

anti-cd56 mab therapy for mcc

anti-tumor

anti-tumor immune

anti-tumor immune responses

antibodies cd8 t cells

antibody

antigen by yeast two-hybrid system

appearance of merkel cell

appearance of merkel cell carcinoma

approved

approved treatment

april

arkansas for medical sciences

article

asgari kaiser permanente northern california

assistant

athens

avelumab

award for innovative

award for innovative therapy

balzer cedars sinai los

balzer cedars sinai los angeles

basal cell

basal cell carcinoma

baseline

baseline imaging

becker amp

bed treatment after positive slnb

being studied by immune design

berlin

bhatia

bhatia spoke

bi

bianca lemos university of washington

bichakjian u michigan ann arbor

biology

biomarker

biomarker analyses

biomarker approach best predicts response

biopsy

blankemeyer

blood

blood antibody levels

bob lutz kathy whiteman

bob lutz kathy whiteman immunogen

body

boise

bone muscle fascia or cartilage

bonnie balzer cedars sinai

bonnie balzer cedars sinai los

boston ma

breslow thickness

bringing

british

british columbia

brownell md phd

bump

byrd

california san francisco

california san francisco xrt

cam 5.2

cancer

cancer care

cancer care alliance

cancer cells

cancer center

cancer institute mcc

cancer institute mcc information

cancer therapy

cancers

carcinoma

carcinoma patients

carcinoma research

care

care alliance

carolyn messner dsw

carolyn messner dsw osw-c

carolyn messner dsw osw-c fapos

cases

cases/year

caused

cd8 t

cd8 t cells

cd8 t cells and prognosis

cedars sinai los angeles

cell

cell carcinoma

cell carcinoma patients

cell carcinoma quantity and quality

cell carcinoma research

cell epitopes from merkel polyomavirus

cell lines

cell lung cancer

cells

cells in the skin

cells that divide

center

center boston ma

center for reconstructive

center for reconstructive surgery

center new york

center new york ny

certain hormones

certifications

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

certifications and licenses

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

challenging

change in tumor size

characteristics

check to uw

checkpoint inhibitors

chemotherapy

chemotherapy drugs

chris bichakjian u michigan ann

chris bichakjian university of michigan

chronic lymphocytic

chronic lymphocytic leukemia

ci

citn-09/keynote-017 trial

click

click to view

clinic

clinical

clinical exam

clinical exam* no pathologic node

clinical photos page

clinical trial

clinical trial of adjuvant interferon

clinical trial of an immune

clinical trial's eligibility

clinical trial's eligibility requirements

clinical trials

clinical trials for mcc

clinical trials in mcc

clinical trials in mcc update

clinical/pathologic stages

clinical/pathologic stages i-ii

clinically

cll

closely by imaging scans

cm maximum tumor dimension

codes

codes for mcc

cohort

cohort b

cohort through jan

coley

colin

collaboration

collaboration with dr

colleagues

colleagues amp

collecting mcc patient outcomes data

columbia

common

company bristol-myers squibb

complementary alternative

completed

comprehensive cancer

comprehensive cancer center

confidence

confirmed via pathological exam

congress

consensus staging system

contact

contact information for the ordering

content

course

covid-19

critical

critical measures

critical measures of prognosis

ct for merkel

ct for merkel the harvard

ct for merkel the mayo

ct scan

ctla-4 inhibitors

cycle

cycles

cytokeratin 20

dad

dana

data

database

decrease

degree

density

department

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

department of laboratory

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

department of laboratory medicine

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

department of laboratory medicine licenses

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

depending on the study

deputy director for skin/cutaneous

deputy director for skin/cutaneous oncology

dermatologist

dermatology

describe

description antibody against pd-1

developing mcc

development of mcc

diagnosis

diagram

dinner

director

director for skin/cutaneous

director for skin/cutaneous oncology

discussion

disease

disease recurrence

disease recurrence and survival

distant

distant metastasis

doctors

doses

download

draining lymph node

dsw osw-c fapos

dsw osw-c fapos faosw

due to a small sample

durable responses

duration of response

eado

edition ajcc staging system

edition staging system

editorial

educational

educational outreach

efficacy

eligibility requirements

email

enroll in clinical

enroll in clinical trials

enrolled

enrolled in the seattle

entirely in selected mcc cases

epidermis

epitopes from merkel polyomavirus oncoproteins

eposter discussion

equal to 2 cm

equal to 2 cm maximum

erica shantha tarabadkar

erica shantha tarabadkar uw

established

et al

et al nejm

et al nejm 2016

eugene j

european

evan

event

evidence of disease

exam* no pathologic node exam

examples of mcc tumors

experience

expert

exploratory biomarker

exploratory biomarker analyses

exploring the role of hedgehog

exposure-response

exposure-response analyses

expression of il12

expression of il12 protein

extensive sun exposure

facilitated discussion

familiar

family

family and friends

fccc philadelphia pa

feature a panel

feature a panel of experts

feedback

feedback email

felt on physical

felt on physical exam

fight

find

first line

fluid

flyer

focused

followed closely by imaging

followed closely by imaging scans

followed over time

found

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

foundation

fred

fred hutch

fred hutchinson cancer research center

frequently

friedrich

friedrich merkel

friends

fruits and vegetables

fund

general health

generous

genetics of mcc

given intravenously

given intravenously or orally

gla-se for merkel cell

gla-se for merkel cell carcinoma

golf

grant

gregg

grief

group

guests

h&n

h&n mcc

handout

hands

harley haynes

harley haynes lectureship

haynes lectureship

healthcare

healthcare provider

healthcare providers

heath

helen

helen leonard

help

higher risk of developing mcc

highlight

history of mcc

honor

hormones

hospital

hutch

hutchinson cancer research center

i.t.-tavo-ep

ibrahim u rochester

ibrahim u rochester ny

icd codes

identify the sentinel

identify the sentinel lymph

identify the sentinel lymph node

iiib patients with a known

il-12

il12

il12 protein

illustrations

imaging

immune

immune checkpoint

immune checkpoint inhibitors

immune evasion

immune evasion mechanisms

immune responses

immune stimulating agent gla-se

immune stimulating therapy

immune suppressed

immune suppression

immune system

immune system to attack

immune therapy clinical

immune therapy clinical trials

immune-stimulating clinical trials for mcc

immunogenic

immunogenic cancer

immunotherapy

immunotherapy trials for mcc

improving

in-field locoregional

in-field locoregional recurrences

included

includes invading tumors

increase

india

information

information that identifies

initial

injectable in skin or possibly

injected at the site

innovative therapy

institution

interact with certain medications

interested

international

international symposium

interview

intravenously or orally

isaac brownell md

isaac brownell md phd

iyer j nghiem p

janet canning

japan

japanese

jayasri iyer u washington

jayasri iyer u washington seattle

jerry

jerry marsden university hospital birmingham

jerry wachter

jerry wachter fund

jim o'leary bob lutz kathy

johnston

join

joined

kaiser permanente northern california

kaplan-meier curves

kathy whiteman immunogen waltham ma

kawasumi

kelly harms university of michigan

keynote-555

kidney or heart transplantation

knew

know

lab

lab at uw

lab team

lab tour

lab tours

laboratory

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

laboratory medicine

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

laboratory medicine licenses

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

laboratory medicine licenses and accreditations

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

layer

lecture

led to systemic

left

left to right

lemos

leonard

lesion

leukemia

liberty

liberty subaru

licenses

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

licenses and accreditations

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

life

limb

limb left

limb right

limb unspecified

line

list

local

local control

local inflammation

local recurrence

localized h&n

localized h&n mcc

locally advanced

location

locoregional recurrences

long-term

look

lower limb

lutz kathy whiteman immunogen

lutz kathy whiteman immunogen waltham

lymph

lymph node

lymph node biopsy

lymph node dissection

lymph node dissection vs nodal

lymph node metastasis

lymph node region

lymph node(s

lymph nodes

lymphatic

lymphatic vessels

lymphocytic leukemia

lymphovascular invasion

madrid

malignant

manage

management

management of mcc

manual 8th edition

mapper mobile app project

mapper mobile app project possibilities

march 21

march 21 2016

marchionini

margin size

marsden university hospital birmingham uk

maryam asgari kaiser permanente northern

masaoki

masaoki kawasumi

mcc

What issues should I be sure to discuss with my physicians?

Merkel cell carcinoma is rare, so it is common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team be knowledgeable, as they will need to execute the plan that MCC specialists will create. Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed about MCC and how to care for patients.

mcc cohort

mcc cohort through jan

mcc differ in appearance

mcc management in ann arbor

mcc patient outcomes data getting

mcc patients

mcc patients from northern california

mcc research

mcc specialist

mcc specialists

mcc staging—new national data

mcc staging—new national data amp

mcc support

mcc support group

mcc tumor

mcc tumor cells

mcc tumors

mcc update on pembrolizumab anti-pd1

mcc-specific checklist for pathology features

mcc-specific survival

mccteam@uw.edu

mcpyv

mcpyv positive

mcpyv positive and negative

mcpyv positive and negative mcc

md phd

measures

measures of prognosis

median

medical

What issues should I be sure to discuss with my physicians?

Merkel cell carcinoma is rare, so it is common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team be knowledgeable, as they will need to execute the plan that MCC specialists will create. Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed about MCC and how to care for patients.

medical advice

medical center

medical center boston ma

medical center new york

medical center new york ny

medical school

medicine

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

medicine licenses

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

medicine licenses and accreditations

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

meet the clinical

meet the clinical trial's eligibility

meeting

melanoma

members

members in merkel cell carcinoma

members of the nghiem

members of the nghiem lab

merkel

merkel cell

merkel cell carcinoma

merkel cell carcinoma patients

merkel cell carcinoma quantity

merkel cell carcinoma research

merkel cell carcinoma-specific t cells

merkel cell carcinomas

merkel cell polyomavirus

merkel cell polyomavirus-small t antigen

merkel cells

merkel dinner

merkel polyomavirus

merkel polyomavirus serology

merkel polyomavirus serology test

merkel the harvard experience amp

merkel the mayo experience amp

merkel virus serology

merkel virus serology test

messner dsw osw-c

messner dsw osw-c fapos

messner dsw osw-c fapos faosw

metastatic

metastatic mcc

mg/kg

michael

michael piepkorn

micrographic surgery

microsurgery

microvascular

milt

milton

milton r

milty

minimal toxicity

mmcc

modeling

mohs micrographic

mohs micrographic surgery

mohs surgery

mole mapper mobile app

mole mapper mobile app project

monica

mortality

multi-institutional trials of anti-cd56 mab

multi-modality mcc management in ann

multidisciplinary

multidisciplinary team

n =

nat'l cancer institute

nat'l cancer institute mcc

nat'l cancer institute mcc information

natalie

national cancer institute

national comprehensive

national comprehensive cancer network®

negative by clinical exam

negative microscopic margins

neha singh

neligan

neoadjuvant

new tumor

new york ny

nghiem

nghiem et al

nghiem et al nejm

nghiem et al nejm 2016

nghiem lab

nghiem lab team

nghiem p

nghiem u washington seattle

nghiem's lab

nghiem's lab at uw

nghiem&#8217

node

node bed treatment after positive

node dissection vs nodal radiation

nodes

nodes negative by clinical

nodes negative by clinical exam

nodes negative by clinical exam*

nodes negative by pathologic exam

nodes positive by clinical

nodes positive by clinical exam

normal merkel

normal merkel cells

normal regulation

nutritional supplementation

nutritional supplementation program

o'leary bob lutz kathy

o'leary bob lutz kathy whiteman

older immune

older immune suppressed

oncologists

oncology

oncoprotein

oncoprotein antibodies

online

online contribution

online support

online support group

option for patients with metastatic

order to determine

organization

origin

orr

os

osterlof

osw-c fapos faosw

outcome compared to node-positive patients

outreach

overview

overview of current clinical trials

page to learn

palpable disease

palpable lymph

palpable lymph nodes

panel of experts

panel of experts including

participating

participating in the adam

participating in the adam trial

participating in this trial

participation in the trial

parvathaneni

pathologic node exam performed

pathological exam

pathological exam performed

patient

patient handout

patient's immune system to attack

patients

patients treated

patients with a known primary

patients with advanced

patients with clinically

patients with cll

patients with localized

patients with mcc

patients with mcpyv negative tumors

patients with metastatic

patients with metastatic mcc

patients with mmcc

patients with recurrent

patients with recurrent locally

patients with recurrent locally advanced

patients with this cancer

patients without palpable

paul

paul nghiem

paul nghiem u washington

paul nghiem u washington seattle

paul nghiem university of washington

paul nghiem uw-seattle

paul nghiem uw-seattle amp

pay

pd-l1

pd1 and tim3 exhaustion markers

pembrolizumab

people

perrott 2003 with permission

personal

personal data

pet vs ct

pet vs ct for merkel

pet-cts in managing mcc

pharmaceutical company bristol-myers

pharmaceutical company bristol-myers squibb

pharmacokinetic

pharmacokinetic modeling

phase ii trial

phd

photos

photos of mmig members

physician

physician assistant

physician prior

physician prior to beginning

physicians

physicians determine

piepkorn

plan

planned 8th edition ajcc

planned 8th edition ajcc staging

planned gifts

planned gifts provide

planned giving

plastic surgery

polyomavirus

polyomavirus serology test

positive and negative

positive and negative mcc

positive and negative mcc cells

positive by clinical exam

positive slnb clnd vs

positive slnb clnd vs xrt

postoperative

postoperative sfrt

potential

present

presentation

presentations

presented

presented on the #8220

primary

primary site

primary tumor

primary tumor invades bone muscle

primary tumor site management amp

prior to beginning

prize

proceed

produce

produce certain hormones

produce oncoprotein antibodies

professional

prognosis

program as some supplements

progress

progress being

project data sphere

proper

proposed ajcc staging system

protein

provide

provider

published

queensland

questions

radiation

radiation entirely in selected mcc

radiation oncology

radiation therapy

radiation to the primary tumor

radiotherapy

randomized trial for adjuvant chemotherapy

rare

rate

ready

received

reconstruction

reconstructive

reconstructive microsurgery

reconstructive surgery

recurrence

recurrence and survival

recurrence free survival

recurrence risk

recurrence risk calculator

recurrence-free survival

recurrent locally

recurrent locally advanced

recurrent or metastatic lesions

region

regional

regional lymph node metastasis

regional lymph nodes

regional nodes

regional or distant

regional or distant metastasis

regulation

relevant

remission

research

research efforts

research scientist

resources

resources page

response

response rate

responses

reviewed

revised mcc staging system

rick

risk

risk of developing

risk of developing mcc

risk of having a recurrence

risk of recurrence

robert royer

row

royer

s presentation

safety

samples

san francisco ca

scan

scientific

scott award

scott award for innovative

scott award for innovative therapy

scout skin cancer outcomes

seattle

seattle cancer care

seattle cancer care alliance

seattle mcc

seattle mcc support

seattle mcc support group

seattle translational

seattle translational tumor

seattle translational tumor research

see

sendai

sentinel

sentinel lymph

sentinel lymph node

sentinel lymph node biopsy

sentinel lymph node(s

september

serology

serology test

serology titer

serve

serve as the principal investigator

serve as touch

serve as touch cells

serves as the basis

sfrt

sherrif ibrahim u

sherrif ibrahim u rochester

sherrif ibrahim u rochester ny

side effects

siegrid yu u of california

siegrid yu ucsf san francisco

significant

signs

signs and symptoms

signs and symptoms of cancer

simpson's dominance index

single

single fraction

sirna-based screening

site

site of origin

size

size tumor includes

size tumor includes invading

size tumor includes invading tumors

skin

skin cancer

skin cancer with clinical trials

skin cancers

skin or possibly lymph

skin or possibly lymph nodes

slnb clnd vs xrt

small cell lung

small cell lung cancer

small sample size

song park university of washington

southern california los angeles

specialist

specialists

spirit

spoke

spread

squamous cell

squamous cell carcinoma

stage

stage iia due

stage iiib patients

stages i-ii

staging

staging manual 8th edition

staging system

staging system for the ajcc

staging—new national data amp

stimulating agent gla-se for merkel

story

studied by immune design

study

study keynote-555

study team

study treatment avelumab

subaru

suggestions

suggestions and feedback

suggestions and feedback email

sun-exposed skin

supplementation program

supplementation program as some supplements

support

support group

surgeon

surgery

surgical

surgical excision

surgical margin

surgical margin size

surgical oncology

surveillance

survival

survival in merkel cell

survival in merkel cell carcinoma

survival outcome compared to node-positive

suspicious lesion

symposium

symptoms

symptoms of cancer

system

system for the ajcc staging

systemic

systemic toxicity

t antigen by yeast two-hybrid

t cell

t cell epitopes from merkel

t cells

t cells in mcc amp

taking

tarbox

tax-deductible online

tax-deductible online contribution

team

What issues should I be sure to discuss with my physicians?

Merkel cell carcinoma is rare, so it is common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team be knowledgeable, as they will need to execute the plan that MCC specialists will create. Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed about MCC and how to care for patients.

test

therapy

therapy clinical trials in mcc

therapy for metastatic mcc

time

tissue

tissues

titer

titer decreases

titers of oncoprotein antibodies

together

tomography scan

tomoko

tomoko akaike

toronto

touch

touch cells

tour

training

translational research

translational tumor

translational tumor research

treated

treating

treatment

treatment after positive slnb clnd

treatment recommendations

trial

trial of an immune stimulating

trial's eligibility requirements

trials

trials for mcc

trials of anti-cd56 mab therapy

trip

tumor

tumor affect survival in mcc

tumor cells

tumor includes invading

tumor includes invading tumors

tumor invades bone muscle fascia

tumor research

tumor samples

tumor viral status

tumor viral status predict drug

tumors

typically

u of california san francisco

u rochester ny

u washington seattle

uncle

uncle milty

univ california san francisco

univ california san francisco xrt

university

university medical

university medical center

university of arkansas for medical

university of birmingham uk

university of southern california

university of southern california los

university of washington

university school of medicine

unknown primary mcc

unknown primary mcc immunobiology

unspecified

update on mcc staging—new national

updated

updates

upper limb

upstaged

useful for all mcc

useful for all mcc patients

uw

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

uw department

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

uw department of laboratory

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

uw department of laboratory medicine

How do I obtain a copy of the University of Washington CLIA and CAP accreditations relating to the serology test?

The certifications and licenses can be found here: UW Department of Laboratory Medicine Licenses and Accreditations

uw medicine

van scott

van scott award

van scott award for innovative

vegetable intake

vessels to the sentinel

vessels to the sentinel lymph

video

videos

view

viral proteins

viral status

viral status predict drug response

virtual

virus

virus-negative

virus-negative cases

virus-negative mcc

visit

visit the clinical photos

visit the clinical photos page

visitors

vs ct for merkel

wachter

wachter fund

wash

wash your hands

washington

website

work

world

xrt monotherapy in most cases

xrt to primary tumor site

yolles

yu u of california san

zent

zoom